Ascelia (Q2 review): All eyes on September meeting - Redeye
Redeye returns with an update on Ascelia after the Q2 report, which contained few surprises. We reiterate our fair value and the company screens "fairly priced" at the moment.
ANNONS
Redeye returns with an update on Ascelia after the Q2 report, which contained few surprises. We reiterate our fair value and the company screens "fairly priced" at the moment.
